期刊文献+

基于层次分析法开展儿童用药循证综合评价 被引量:12

Evidence-based Comprehensive Pediatric Drug Evaluation Involved with Analytic Hierarchy Process
下载PDF
导出
摘要 目的:建立我国儿童临床用药综合评价方法。方法:采用文献研究法和专家咨询法,梳理综合评价方法建立的理论基础及可行性,采用层次分析法建立儿童用药循证综合评价方法。结果:基于层次分析原理,通过构建指标体系、确定指标权重、构建证据体和证据质量评价、以及综合评分四个过程开展儿童药物循证综合评价,并以六种大环内酯类药物为例进行实证研究,证实其可行性。结论:以层次分析法为基础的儿童用药循证综合评价方法能客观地衡量多个药品之间的优劣关系,为儿童临床合理用药提供依据。 Objective:To set up a method for comprehensive evaluation of clinical medication in pediatrics in China.Methods:After literature research and expert consultation,this comprehensive evaluation method was built on the analytic hierarchy process theory.Results:This method contain four processes,including index system development,index weight balancing,evidence matrix and quality construction,and integrated assessment process based on analytic hierarchy process.Its feasibility was confirmed by a practical empirical research of six macrolides.Conclusion:The evidence-based comprehensive pediatric drug evaluation method could weigh the pros and cons among different drugs and provide evidence for rational drug use.
作者 贾露露 孟瑶 刘亦韦 尉耘翠 郭志 彭晓霞 王晓玲 Jia Lulu Meng Yao Liu Yiwei Yu Yuncui Guo Zhigang Peng Xiaoxia Wang Xiaoling(Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China School of Pharmaceutical Sciences, Peking University)
出处 《药物流行病学杂志》 CAS 2016年第10期601-605,共5页 Chinese Journal of Pharmacoepidemiology
基金 国家卫计委药政司委托课题(编号:药政[2015]15号) 中国-世卫组织2014-2015双年度合作项目(编号:WPCHN1408195,5.1,61775)
关键词 层次分析法 儿童药物 循证 综合评价方法 Analytic hierarchy process Pediatric drug Evidence-based evaluation Comprehensive evaluation method
  • 相关文献

参考文献5

二级参考文献30

  • 1Plehn J F,Davis B R,Sacks F M,et al.Reduction of stroke incidence after myocardial infarction with pravastatin:the Cholesterol and Recurrent Events(CARE)study.The Care Investigators.Circulation,1999,9(9):216-223. 被引量:1
  • 2Law MR,Wald NJ,Rudnicka AR.Quantifying effect of statins on low density lipoprotein cholesterol,ischaemic heart disease,and stroke:systematic review and meta-analysis.BMJ.2003,326(7404):1423-1427. 被引量:1
  • 3Scott M.Grundy,James I.Cleeman,C.Noel Bairey Merz,et al.Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines.Circulation.2004,110(2):227-239. 被引量:1
  • 4LaRosa JC,Grundy SM,Waters DD.Intensive lipid lowering withatorvastatin in patients with stable coronary disease.N Engl J Med,2005,352(14):1425-1435. 被引量:1
  • 5Baigent C,Keech A,Kearney PM.Efficacy and safety of cholesterol lowering treatment:prospective meta analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet,2005,366(9493):1267-1278. 被引量:1
  • 6陈新谦,金有豫,汤光.新编药物学.16版.北京:人民卫生出版社,2003:664-697. 被引量:1
  • 7Pasceri V,Patti G,Nusca A,et al.Randomized trial of atorvastat in for reduction of myocardial damage during coronary intervention:Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study.Circulation,2004,110(6):674-678. 被引量:1
  • 8柳晓云,马明恺,郑卯昵,卢晓敏,毛英姿.儿童热惊厥临床相关问题的研究[J].浙江医学,1998,20(5):269-270. 被引量:2
  • 9唐美君.儿童用药特点及用药原则的浅析[J].中国当代医药,2009,16(10):159-160. 被引量:7
  • 10董艳,程力军,董利红,华丽霞.基层医院处方评价制度的实践体会[J].中国药业,2009,18(13):47-49. 被引量:9

共引文献45

同被引文献134

引证文献12

二级引证文献87

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部